FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551032005> ?p ?o ?g. }

• W2551032005 endingPage "1321" @default.
• W2551032005 startingPage "1321" @default.
• W2551032005 abstract "Abstract Introduction: the addition of Rituximab to standard chemotherapy CHOP improves the outcome of advanced stage B-DLCL, however pts at high risk continue to have a poor outcome. The combination of Rituximab with dose-dense and intensified chemotherapy is still poorly studied so far. Patients and methods: from January 2001 to June 2004, 92 previously untreated pts <61 yrs affected by B-DLCL at age-adjusted IPI intermediate-high (IH) or high (H) risk and/or with BM involvement were enrolled. They were treated with an intensified chemoimmunotherapy regimen R-MegaCEOP (Rituximab 375 mg/m2 day 1, Cyclophosphamide 1200 mg/m2 + Epirubicin 110 mg/m2 + Vincristine 1.4 mg/m2 day 3 and Prednisone 40 mg/m2 day 3 to 7) every 14 days with G-CSF support for 4 courses ± 2 courses of DHAP in case of less than PR; pts in CR or PR received two courses of intensified chemotherapy R-MAD: Mitoxantrone 8 mg/m2 + ARA-C 2000 mg/m2/12h + Dexamethasone 4 mg/m2/12h days 1 to 3 and Rituximab 375 mg/m2 day 4 and before peripheral blood stem cell (PBSC) harvest as in vivo purging followed by myeloablative therapy with BEAM and ASCT± IF RT to previous bulky areas. All pts were given antibacterial and antifungal prophylaxis throughout the whole treatment. At diagnosis, PCR molecular analysis for the presence of Ig heavy chain gene rearrangement was analyzed on lymphonode or BM sample in 37 patients. Results: Median age was 47 years (19–60); 6% were at LI risk (enrolled because of BM involvement), 53% at IH and 41% at H risk according to IPI; 27% had BM involvement and 80% LDH level >normal. So far, 72 pts who completed the treatment are evaluable for response and toxicity. Fifty-seven pts (79%) achieved a CR;one a PR (1.4%); ten pts (14%) progressed before (7 pts) or shortly after (3 pts) ASCT. Four pts (5.6%) died of infectious toxicities (2 bacterial sepsis and 2 pneumonia) which occurred during neutropenic period post MAD (3 pts) or after ASCT (1 pt). Sixteen pts did not completed the planned treatment because of disease progression before ASCT (7 pts) or inadequate PBSC yield (5 pts) or toxicity (4 pts). With a median follow-up of 2 yrs, only 2 pts relapsed. Two-yrs FFS and OS were: 72% and 77%. Fourteen pts developed infections (WHO>2): 2 interstitial pneumonia, 5 neutropenic Gram- and 2 Gram+ sepsis, 1 disseminated herpes zoster, 1 Ps. Aeruginosa and 1 Staph. aureus pneumonia, 1 bacterial pancreatitis and 1 perianal abscess. A molecular marker has been detected at diagnosis in 27 patients. So far, 12 PBSC harvest has been analyzed and 11/12 were PCR negative. Conclusions: this interim analysis suggests that the concurrent use of Rituximab with dose-dense and high dose chemotherapy followed by myeloablative therapy with ASCT support is effective to achieve a high CR and a high 2-yr FFS rate in a group of B-DLCL patients at poor prognosis. Furthermore, the addition of Rituximab during mobilitation procedure with R-MAD may allow to collect lymphoma-free PBSC harvest." @default.
• W2551032005 created "2016-11-30" @default.
• W2551032005 creator A5000403848 @default.
• W2551032005 creator A5005495487 @default.
• W2551032005 creator A5005558035 @default.
• W2551032005 creator A5013541130 @default.
• W2551032005 creator A5015825420 @default.
• W2551032005 creator A5033131356 @default.
• W2551032005 creator A5034123305 @default.
• W2551032005 creator A5039029593 @default.
• W2551032005 creator A5041337278 @default.
• W2551032005 creator A5042850515 @default.
• W2551032005 creator A5054623894 @default.
• W2551032005 creator A5058459820 @default.
• W2551032005 creator A5065647908 @default.
• W2551032005 creator A5069596141 @default.
• W2551032005 creator A5070003191 @default.
• W2551032005 creator A5071466957 @default.
• W2551032005 creator A5076114231 @default.
• W2551032005 creator A5076236981 @default.
• W2551032005 creator A5078492047 @default.
• W2551032005 date "2004-11-16" @default.
• W2551032005 modified "2023-09-30" @default.
• W2551032005 title "Concurrent Rituximab with Dose-Dense MegaCEOP Chemotherapy and High Dose Mitoxantrone, Ara-C and Dexamethasone (MAD) Followed by BEAM and Autologous Stem Cell Transplantation (ASCT) Is Feasible and Effective in High Risk Diffuse Large B-Cell Lymphoma (B-DLCL): A Multicenter Pilot Study." @default.
• W2551032005 doi "https://doi.org/10.1182/blood.v104.11.1321.1321" @default.
• W2551032005 hasPublicationYear "2004" @default.
• W2551032005 type Work @default.
• W2551032005 sameAs 2551032005 @default.
• W2551032005 citedByCount "0" @default.
• W2551032005 crossrefType "journal-article" @default.
• W2551032005 hasAuthorship W2551032005A5000403848 @default.
• W2551032005 hasAuthorship W2551032005A5005495487 @default.
• W2551032005 hasAuthorship W2551032005A5005558035 @default.
• W2551032005 hasAuthorship W2551032005A5013541130 @default.
• W2551032005 hasAuthorship W2551032005A5015825420 @default.
• W2551032005 hasAuthorship W2551032005A5033131356 @default.
• W2551032005 hasAuthorship W2551032005A5034123305 @default.
• W2551032005 hasAuthorship W2551032005A5039029593 @default.
• W2551032005 hasAuthorship W2551032005A5041337278 @default.
• W2551032005 hasAuthorship W2551032005A5042850515 @default.
• W2551032005 hasAuthorship W2551032005A5054623894 @default.
• W2551032005 hasAuthorship W2551032005A5058459820 @default.
• W2551032005 hasAuthorship W2551032005A5065647908 @default.
• W2551032005 hasAuthorship W2551032005A5069596141 @default.
• W2551032005 hasAuthorship W2551032005A5070003191 @default.
• W2551032005 hasAuthorship W2551032005A5071466957 @default.
• W2551032005 hasAuthorship W2551032005A5076114231 @default.
• W2551032005 hasAuthorship W2551032005A5076236981 @default.
• W2551032005 hasAuthorship W2551032005A5078492047 @default.
• W2551032005 hasConcept C126322002 @default.
• W2551032005 hasConcept C141071460 @default.
• W2551032005 hasConcept C143998085 @default.
• W2551032005 hasConcept C2776063141 @default.
• W2551032005 hasConcept C2776694085 @default.
• W2551032005 hasConcept C2776755627 @default.
• W2551032005 hasConcept C2777063308 @default.
• W2551032005 hasConcept C2778336483 @default.
• W2551032005 hasConcept C2778850193 @default.
• W2551032005 hasConcept C2779050716 @default.
• W2551032005 hasConcept C2779338263 @default.
• W2551032005 hasConcept C2779429289 @default.
• W2551032005 hasConcept C2780401358 @default.
• W2551032005 hasConcept C2780653079 @default.
• W2551032005 hasConcept C2780790343 @default.
• W2551032005 hasConcept C2780923524 @default.
• W2551032005 hasConcept C2781413609 @default.
• W2551032005 hasConcept C2911091166 @default.
• W2551032005 hasConcept C71924100 @default.
• W2551032005 hasConcept C90924648 @default.
• W2551032005 hasConceptScore W2551032005C126322002 @default.
• W2551032005 hasConceptScore W2551032005C141071460 @default.
• W2551032005 hasConceptScore W2551032005C143998085 @default.
• W2551032005 hasConceptScore W2551032005C2776063141 @default.
• W2551032005 hasConceptScore W2551032005C2776694085 @default.
• W2551032005 hasConceptScore W2551032005C2776755627 @default.
• W2551032005 hasConceptScore W2551032005C2777063308 @default.
• W2551032005 hasConceptScore W2551032005C2778336483 @default.
• W2551032005 hasConceptScore W2551032005C2778850193 @default.
• W2551032005 hasConceptScore W2551032005C2779050716 @default.
• W2551032005 hasConceptScore W2551032005C2779338263 @default.
• W2551032005 hasConceptScore W2551032005C2779429289 @default.
• W2551032005 hasConceptScore W2551032005C2780401358 @default.
• W2551032005 hasConceptScore W2551032005C2780653079 @default.
• W2551032005 hasConceptScore W2551032005C2780790343 @default.
• W2551032005 hasConceptScore W2551032005C2780923524 @default.
• W2551032005 hasConceptScore W2551032005C2781413609 @default.
• W2551032005 hasConceptScore W2551032005C2911091166 @default.
• W2551032005 hasConceptScore W2551032005C71924100 @default.
• W2551032005 hasConceptScore W2551032005C90924648 @default.
• W2551032005 hasIssue "11" @default.
• W2551032005 hasLocation W25510320051 @default.
• W2551032005 hasOpenAccess W2551032005 @default.
• W2551032005 hasPrimaryLocation W25510320051 @default.
• W2551032005 hasRelatedWork W136411592 @default.
• W2551032005 hasRelatedWork W1593028635 @default.
• W2551032005 hasRelatedWork W1976189874 @default.
• W2551032005 hasRelatedWork W2016341751 @default.
• W2551032005 hasRelatedWork W2088541499 @default.

• next